Business
BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts Company plans to
About this update from Bioxcel Therapeutics, Inc.
[{"type":"text","content":"BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts Company plans to continue evaluation of BXCL701 combination as potentially differentiated approach for mCRPC patients Results support BXCL701’s potential to extend checkpoint inhibitor therapy into cold tumor settings NEW HAVEN, Conn., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced results from its ongoing Phase 2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype. Results will be highlighted in two poster presentations at the 2022 ASCO Genitourinary Cancers Symposium on February 17, 2022. “There are, unfortunately, very few treatment options available for patients with mCRPC, especially those with SCNC, for which there are no approved therapies,” said Rahul Aggarwal, M.D., Associate Director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center and Associate Professor of Hematology/Oncology, UCSF. “These data demonstrate the potential of BXCL701 plus pembrolizumab to redefine the standard of care for patients with advanced disease. The results were particularly encouraging given that patients were not preselected on the basis of predictors of immune response in prostate cancer.” KEY SCNC FINDINGS In the evaluable patient cohort (n = 15), 5 (33%) patients achieved a composite response at the planned interim analysis.In patients with measurable disease (n = 12), RECIST-defined partial response was observed in 4 (33%) patients (3 confirmed responses) and the disease control rate, defined as complete response (CR) + partial response (PR) + stable disease (SD), was 58% (7 patients).3 (17%) patients experienced serious adverse events (AEs) possibly related to BXCL701 or pembrolizumab, and 4 (22%) patients discontinued any drug due to AEs. KEY ADENOCARCINOMA FINDINGS In the evaluable patient cohort (n = 29), 6 (21%) patients achieved a composite response.In patients with measurable disease (n = 18),...